Management of non-ovarian cancer malignant ascites through indwelling catheter drainage

BMC Palliative Care

Table 1 Seventy-eight patients’ general and ascites related characteristics (N = 78)

General characteristics	N.	%	Ascites related	N	%
Age			Serum albumin(g/L)
<=50	21	26.9	<=30	32	41.0
50–70	43	55.1	>30	46	59.0
> = 70	14	17.9	Color
Gender			Yellow	15	19.2
Male	35	44.9	Brown	43	55.1
Female	43	55.1	Red	20	25.6
Malignancy type			Gravity
GI group^a	48	61.5	>1.012	23	29.5
Others^b	16	20.5	<=1.012	55	70.5
Unknown	14	17.9	Rivalta test
Metastasis			-	22	28.2
Liver	46	59.0	+	47	60.2
Lung	16	20.5	(++ − +++)	9	11.5
Bone	12	15.4	Ascites LDH
Treatment History			>200	45	57.7
Surgery	33	42.3	<=200	33	42.3
Chemotherapy	35	44.9	Removed ascites volume
Radiotherapy	35	44.9	<=3000 ml	16	20.5
Others	22	28.2	3000–5000 ml	25	32.1
Diuretics			> = 5000 ml	37	47.4
Aldosterone antagonist only	35	44.9
Frusemide only	10	12.8
Combination of both	25	32.1

Rivalta Test The Rivalta test was used in order to differentiate a transudate from an exudate. A positive the test meant high protein concentration of ascite fluid and possibly a relationship with Spontaneous bacterial peritonitis (SBP)
Ascites LDH Ascites lactate dehydrogenase was used to differentiate malignant transudate from benign transudate
^aGI group: The gastrointestinal group included hepatic cancer, pancreatic cancer, colorectal cancer and etc
^bOther primary tumors included lung, breast, renal, etc. Unknown is for patients that had malignant proof but not primary proof

ISSN: 1472-684X